Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Large B-cell Lymphoma
Related studies linked through entity extraction aliases.
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE3
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
- Status
- RECRUITING
- Phase
- PHASE1
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
- Status
- AVAILABLE
- Phase
- N/A
Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Expanded Access Program for Epcoritamab
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
- Status
- RECRUITING
- Phase
- PHASE2
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Efficacy of BZ019 in Large B-cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
PD-L1 PET-imaging During CAR T-cell Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
- Status
- RECRUITING
- Phase
- N/A
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
- Status
- COMPLETED
- Phase
- PHASE4
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
CAR-T Followed by Bispecific Antibodies
- Status
- RECRUITING
- Phase
- PHASE2